• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » KCR expands in the U.S. market, opens Boston location

KCR expands in the U.S. market, opens Boston location

May 9, 2017
CenterWatch Staff

KCR, a full service CRO, has announced that it will be moving to a new office in Boston, Massachusetts. The move is another milestone in the company strategy to be closer to partners and clients at the heart of the East Coast biotech and pharma hub.

“We are very excited about the new location in Boston and the ability to serve our U.S. clients on the same ground,” said Mike Jagielski, CEO and president of KCR. “Boston is home to many life sciences companies, and we are proud to be part of this community.”

The Boston area is a top pharma and biopharma hub with Massachusetts ranked the most innovative U.S. state by Bloomberg (Dec, 2016). The new KCR office, located at Rowes Wharf downtown, translates into a perfect location to support innovative R&D projects.

“KCR continues its growth strategy by expanding its capacities to provide clients with customized, reliable and high-quality clinical research services,” added Jagielski. “With our new Boston location, our U.S. presence as well as our strong East—West footprint across 20 countries in Europe, we are uniquely positioned to engage in the most challenging clinical research studies. This is another extraordinary achievement, given our 20th anniversary being celebrated in 2017,” he summarized. Visit KCR to learn more.

Upcoming Events

  • 12Apr

    The Participant Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing